<DOC>
	<DOC>NCT01846663</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.</brief_summary>
	<brief_title>Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy</brief_title>
	<detailed_description />
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Male or nonpregnant, nonbreast feeding female ≥ 18 years old In remission from demonstrated overt HE Had ≥1 episode of overt HE associated with liver disease within the last 6 months MELD score of ≥ 19 Has a close family member or other personal contact who is familiar with the subject's HE, can provide continuing oversight to the subject and is willing to be available to the subject during the conduct of the trial HIV History of tuberculosis infection Chronic respiratory insufficiency Current infection and receiving antibiotics Renal insufficiency requiring dialysis Active spontaneous bacterial peritonitis infection Intestinal obstruction or has inflammatory bowel disease Active malignancy within the last 5 years Current GI bleeding or has had a GI hemorrhage within past 3 months Anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hepatic Encephalopathy</keyword>
	<keyword>Liver Failure</keyword>
	<keyword>Hepatic Insufficiency</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Rifaximin</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>